- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Pharming Group NV (PHAR)

- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: PHAR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $31
1 Year Target Price $31
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -20.99% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.15B USD | Price to earnings Ratio - | 1Y Target Price 31 |
Price to earnings Ratio - | 1Y Target Price 31 | ||
Volume (30-day avg) 3 | Beta 0.18 | 52 Weeks Range 7.50 - 17.86 | Updated Date 12/6/2025 |
52 Weeks Range 7.50 - 17.86 | Updated Date 12/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 0.11% | Operating Margin (TTM) 26.65% |
Management Effectiveness
Return on Assets (TTM) 5.76% | Return on Equity (TTM) 0.03% |
Valuation
Trailing PE - | Forward PE 55.56 | Enterprise Value 1098961433 | Price to Sales(TTM) 3.17 |
Enterprise Value 1098961433 | Price to Sales(TTM) 3.17 | ||
Enterprise Value to Revenue 3.03 | Enterprise Value to EBITDA 24.57 | Shares Outstanding 68514762 | Shares Floating 491681298 |
Shares Outstanding 68514762 | Shares Floating 491681298 | ||
Percent Insiders - | Percent Institutions 0.09 |
Upturn AI SWOT
Pharming Group NV
Company Overview
History and Background
Pharming Group NV was founded in 1988 and is headquartered in Leiden, Netherlands. It's a biopharmaceutical company dedicated to developing and commercializing innovative protein replacement therapies for rare genetic diseases and specialty products. Significant milestones include the development and approval of Ruconestu00ae and the expansion of its pipeline.
Core Business Areas
- Protein Replacement Therapies: Focuses on developing and commercializing recombinant human proteins for rare genetic diseases. Ruconestu00ae is the primary product in this segment.
- Specialty Products: Development and commercialization of specialty pharmaceutical products. This segment also seeks to in-license/out-license opportunities to expand the Pharming Group NV pipeline of assets.
Leadership and Structure
Pharming Group NV is led by a board of directors and a management team headed by CEO Sijmen de Vries. The organizational structure is functional, with departments dedicated to R&D, commercial operations, and corporate affairs.
Top Products and Market Share
Key Offerings
- Ruconestu00ae (C1-esterase inhibitor [recombinant]): Ruconestu00ae is a recombinant human C1 esterase inhibitor used for the treatment of acute angioedema attacks in patients with hereditary angioedema (HAE). It is marketed in the US, EU and other territories. While specific market share data is difficult to determine, Ruconestu00ae holds a significant portion of the on-demand HAE treatment market. Revenue contribution is significant, constituting a large portion of Pharming Group NV's revenue. Competitors include Takeda's Firazyru00ae and BioCryst Pharmaceuticals' Orladeyou00ae (for prophylaxis).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, regulatory hurdles, and intense competition. The market for rare disease treatments is growing, driven by increasing awareness and advancements in diagnostics and therapeutics.
Positioning
Pharming Group NV is positioned as a specialist in protein replacement therapies for rare diseases. Its competitive advantage lies in its expertise in recombinant protein technology and its established commercial infrastructure for Ruconestu00ae.
Total Addressable Market (TAM)
The total addressable market for HAE therapies is estimated to be several billion dollars. Pharming Group NV is positioned to capture a significant portion of this market through continued commercialization of Ruconestu00ae and the development of new therapies.
Upturn SWOT Analysis
Strengths
- Established product (Ruconestu00ae)
- Expertise in recombinant protein technology
- Strong commercial infrastructure
- Focus on rare diseases
Weaknesses
- Reliance on a single major product (Ruconestu00ae)
- Relatively small company size
- High R&D expenses
- Susceptibility to competition from larger pharmaceutical companies
Opportunities
- Expansion into new markets
- Development of new therapies for rare diseases
- Strategic partnerships and acquisitions
- Increased awareness of rare diseases
Threats
- Competition from existing and emerging therapies
- Regulatory challenges
- Pricing pressures
- Patent expirations
Competitors and Market Share
Key Competitors
- TAK
- BCRX
- KALV
Competitive Landscape
Pharming Group NV competes with larger pharmaceutical companies in the HAE market. Its advantage lies in its specialized focus and recombinant protein expertise, but it faces challenges related to resources and market reach compared to its competitors.
Major Acquisitions
Nil
- Year: 2024
- Acquisition Price (USD millions): 0
- Strategic Rationale: N/A
Growth Trajectory and Initiatives
Historical Growth: Historical growth information is to be taken from actuals.
Future Projections: Future Projections data is to be taken from actuals.
Recent Initiatives: Pharming Group NV has focused on expanding the commercial reach of Ruconestu00ae, developing new formulations, and exploring new indications. They are working to in-license products to expand their portfolio and acquire additional products and/or companies to become a larger company
Summary
Pharming Group NV is a biopharmaceutical company focused on rare diseases, primarily hereditary angioedema (HAE). Ruconestu00ae, their main product, has established a solid position in the market. The company needs to continue to diversify its product portfolio beyond Ruconest to mitigate risk. Competition in the HAE market remains intense, requiring strategic marketing and further innovation.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pharming Group NV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-12-23 | CEO & Executive Director Mr. Fabrice Chouraqui Ph.D., Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 404 | Website https://www.pharming.com |
Full time employees 404 | Website https://www.pharming.com | ||
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. It has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
Home 

